Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001213900-20-030519
Filing Date
2020-10-07
Accepted
2020-10-07 17:00:17
Documents
5
Period of Report
2020-11-18
Effectiveness Date
2020-10-07

Document Format Files

Seq Description Document Type Size
1 DEFINITIVE PROXY STATEMENT ea127710-def14a_actinium.htm DEF 14A 628695
2 GRAPHIC img_001.jpg GRAPHIC 14660
3 GRAPHIC img_002.jpg GRAPHIC 5041
4 GRAPHIC proxy_001.jpg GRAPHIC 232593
5 GRAPHIC proxy_002.jpg GRAPHIC 314630
  Complete submission text file 0001213900-20-030519.txt   1373387
Mailing Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016
Business Address 275 MADISON AVENUE, 7TH FLOOR NEW YORK NY 10016 646-677-3875
Actinium Pharmaceuticals, Inc. (Filer) CIK: 0001388320 (see all company filings)

EIN.: 880378336 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-36374 | Film No.: 201229574
SIC: 2834 Pharmaceutical Preparations